<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00011986</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-0182</org_study_id>
    <secondary_id>NCI-2012-02376</secondary_id>
    <secondary_id>SWOG-G0182</secondary_id>
    <secondary_id>CDR0000068467</secondary_id>
    <secondary_id>ISRCTN41636183</secondary_id>
    <secondary_id>MRC-ICON5</secondary_id>
    <secondary_id>ECOG-G0182</secondary_id>
    <secondary_id>GOG-0182</secondary_id>
    <secondary_id>GOG-0182</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT00011986</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer</brief_title>
  <official_title>A Phase III Randomized Trial Of Paclitaxel And Carboplatin Versus Triplet Or Sequential Doublet Combinations In Patients With Epithelial Ovarian Or Primary Peritoneal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynecologic Oncology Group</source>
  <brief_summary>
    <textblock>
      Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop
      growing or die. It is not yet known which combination chemotherapy regimen is most effective
      in treating ovarian epithelial cancer and peritoneal cancer. Randomized phase III trial to
      compare the effectiveness of various combination chemotherapy regimens in treating patients
      who have stage III or stage IV ovarian cancer or primary peritoneal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Compare the efficacy of paclitaxel and carboplatin with or without gemcitabine, doxorubicin
      HCl liposome, or topotecan, in terms of overall and progression-free survival, in patients
      with stage III or IV ovarian epithelial or serous primary peritoneal carcinoma.

      Determine the response rate in patients with measurable disease treated with these regimens.

      Compare the toxic effects of these regimens in these patients. Compare the complications in
      patients treated with these regimens. Determine the dose-intensity and cumulative dose
      delivery for these regimens in these patients.

      OUTLINE:

      This is a randomized, multicenter study. Patients are stratified into 1 of 3 strata according
      to extent of residual disease and plans for interval cytoreductive surgery: Stratum A:
      Optimal (microscopic or macroscopic) residual disease without plans for surgery Stratum B:
      Suboptimal residual disease without plans for surgery Stratum C: Suboptimal residual disease
      with plans for surgeryPatients are randomized to 1 of 5 treatment arms. Arm I: Patients
      receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment
      continues every 3 weeks for 8 courses in the absence of disease progression or unacceptable
      toxicity. Arm II: Patients receive chemotherapy as in arm I and gemcitabine IV over 30
      minutes on days 1 and 8. Treatment continues as in arm I. Arm III: Patients receive
      chemotherapy as in arm I during courses 1-8 and doxorubicin HCl liposome IV over 1 hour on
      day 1 during courses 1, 3, 5, and 7. Treatment continues as in arm I. Arm IV: Patients
      receive topotecan IV over 30 minutes on days 1-3 and carboplatin IV over 30 minutes on day 3.
      Treatment continues every 3 weeks for 4 courses. Patients then receive 4 courses of arm I
      chemotherapy. Arm V: Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and
      carboplatin IV over 30 minutes on day 8. Treatment continues every 3 weeks for 4 courses.
      Patients then receive 4 courses of arm I chemotherapy. Patients with initial unresectable or
      suboptimal residual disease (more than 1 cm) may undergo interval cytoreductive surgery
      between courses 4 and 5 of chemotherapy. Patients are followed every 3 months for 2 years and
      then every 6 months.

      PROJECTED ACCRUAL: Approximately 4,000-5,000 patients (800-1,000 per treatment arm) will be
      accrued for this study within 3.5-5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 9 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>From the date of enrollment to first progression or death or last contact, if alive and progression free.</time_frame>
    <description>Hazard ratio for progression free survival. All hazard ratios are expressed relative to the reference regimen: Carbo/taxol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and Severity of Observed Adverse Effects Assessed by Common Toxicity Criteria Version 2.0</measure>
    <time_frame>Up to 9 years</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">3882</enrollment>
  <condition>Primary Peritoneal Carcinoma</condition>
  <condition>Stage III Ovarian Cancer</condition>
  <condition>Stage IV Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment continues every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and gemcitabine IV over 30 minutes on days 1 and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive chemotherapy as in arm I during courses 1-8 and doxorubicin HCl liposome IV over 1 hour on day 1 during courses 1, 3, 5, and 7. Treatment continues as in arm I.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive topotecan IV over 30 minutes on days 1-3 and carboplatin IV over 30 minutes on day 3. Treatment continues every 3 weeks for 4 courses. Patients then receive 4 courses of arm I chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 8. Treatment continues every 3 weeks for 4 courses. Patients then receive 4 courses of arm I chemotherapy. Patients with initial unresectable or suboptimal residual disease (more than 1 cm) may undergo interval cytoreductive surgery between courses 4 and 5 of chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
    <arm_group_label>Arm V</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>TAX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
    <arm_group_label>Arm V</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm V</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>dFdCyd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Liposomal Doxorubicin Hydrochloride</intervention_name>
    <arm_group_label>Arm III</arm_group_label>
    <other_name>doxorubicin HCl liposome</other_name>
    <other_name>TLC D-99</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm IV</arm_group_label>
    <other_name>Hycamtin</other_name>
    <other_name>SKF S-104864-A</other_name>
    <other_name>TOPO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Conventional Surgery</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Arm V</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed stage III or IV ovarian epithelial or serous
             primaryperitoneal carcinoma

          -  The following are ineligible:

               -  Germ cell tumors

               -  Sex cord-stromal tumors

               -  Carcinosarcomas

               -  Mixed Mullerian tumors or carcinosarcomas

               -  Metastatic carcinomas from other sites to theovary

               -  Low malignant potential tumors, including micropapillary serouscarcinomas

               -  Mucinous primary peritoneal carcinoma

          -  Prior ovarian low malignant potential tumor (borderline carcinoma) that was surgically
             resected with subsequent development of invasive adenocarcinoma allowed if no prior
             chemotherapy

          -  Optimal (no greater than 1 cm) or suboptimal residual disease after initial surgery

          -  Prior breast cancer allowed provided the following are true:

               -  Disease-free for more than 5 years

               -  No prior cytotoxic chemotherapy for breast cancer

          -  Prior or concurrent primary endometrial cancer allowed if the following conditions are
             met:

               -  Stage no greater than IB

               -  Less than 3 mm invasion without vascular or lymphatic invasion

               -  No poorly differentiated subtypes, including papillary serous, clear cell, or
                  other FIGO grade 3 lesions

          -  Performance status - GOG 0-2

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  AST no greater than 2.5 times ULN

          -  Alkaline phosphatase no greater than 2.5 times ULN

          -  No acute hepatitis

          -  Creatinine no greater than 1.5 times ULN

          -  No unstable angina

          -  No myocardial infarction within the past 6 months

          -  No evidence of abnormal cardiac conduction (e.g., bundle branch block, heart block)
             unless stable for the past 6 months

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No greater than grade 1 sensory or motor neuropathy

          -  No active infection that requires antibiotics

          -  No other invasive malignancy within the past 5 years except nonmelanoma skin cancer

          -  No severe or ongoing gastrointestinal bleeding that requires blood product support

          -  See Disease Characteristics

          -  Prior chemotherapy for cancer involving the abdominal cavity or pelvis allowed
             provided the following are true:

               -  More than 3 years since prior therapy

               -  No evidence of recurrent disease

          -  No prior radiotherapy to any portion of the abdominal cavity or pelvis

          -  Prior radiotherapy for localized breast, head and neck, or skin cancer allowed
             provided the following are true:

               -  More than 3 years since prior therapy

               -  No evidence of recurrent disease

          -  See Disease Characteristics

          -  No more than 12 weeks since prior surgical resection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Bookman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecologic Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>February 18, 2014</results_first_submitted>
  <results_first_submitted_qc>March 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 19, 2016</results_first_posted>
  <last_update_submitted>March 17, 2016</last_update_submitted>
  <last_update_submitted_qc>March 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Received began 1/29/2001 and ended 1/28/2003. This was an interventional trial involving patients enrolled from the United States (US), Canada, United Kingdom (UK), Italy, Australia, and New Zealand.</recruitment_details>
      <pre_assignment_details>This study involved patients enrolled from two cooperative groups with the plan to combine data. 3882 patients were enrolled from one cooperative group and 430 from the other. This report includes those patients from both groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Carbo/Taxol</title>
          <description>Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles</description>
        </group>
        <group group_id="P2">
          <title>Carbo/Taxol/Gemcitabine</title>
          <description>Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Gemcitabine 800 mg/m2/dIV on days 1 and 8 x 8 cycles</description>
        </group>
        <group group_id="P3">
          <title>Carbo/Taxol/Doxil</title>
          <description>Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Doxil 30 mg/m2 IV every other cycle on day 1 x 8 cycles</description>
        </group>
        <group group_id="P4">
          <title>Carbo/Topotecan - Carbo/Taxol</title>
          <description>Topotecan 1.25 mg/m2/dIV days 1-3 plus Carboplatin AUC 5 IV on day 3 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles</description>
        </group>
        <group group_id="P5">
          <title>Carbo/Gemcitabine - Carbo/Taxol</title>
          <description>Gemcitabine 1000 mg/m2/dIV on days 1 and 8 plus Carboplatin AUC 6 IV on day 8 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="864"/>
                <participants group_id="P2" count="864"/>
                <participants group_id="P3" count="862"/>
                <participants group_id="P4" count="861"/>
                <participants group_id="P5" count="861"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Initiated Treatment</title>
              <participants_list>
                <participants group_id="P1" count="862"/>
                <participants group_id="P2" count="860"/>
                <participants group_id="P3" count="854"/>
                <participants group_id="P4" count="846"/>
                <participants group_id="P5" count="851"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="864"/>
                <participants group_id="P2" count="864"/>
                <participants group_id="P3" count="862"/>
                <participants group_id="P4" count="861"/>
                <participants group_id="P5" count="861"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Carbo/Taxol</title>
          <description>Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles</description>
        </group>
        <group group_id="B2">
          <title>Carbo/Taxol/Gemcitabine</title>
          <description>Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Gemcitabine 800 mg/m2/dIV on days 1 and 8 x 8 cycles</description>
        </group>
        <group group_id="B3">
          <title>Carbo/Taxol/Doxil</title>
          <description>Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Doxil 30 mg/m2 IV every other cycle on day 1 x 8 cycles</description>
        </group>
        <group group_id="B4">
          <title>Carbo/Topotecan - Carbo/Taxol</title>
          <description>Topotecan 1.25 mg/m2/dIV days 1-3 plus Carboplatin AUC 5 IV on day 3 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles</description>
        </group>
        <group group_id="B5">
          <title>Carbo/Gemcitabine - Carbo/Taxol</title>
          <description>Gemcitabine 1000 mg/m2/dIV on days 1 and 8 plus Carboplatin AUC 6 IV on day 8 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="864"/>
            <count group_id="B2" value="864"/>
            <count group_id="B3" value="862"/>
            <count group_id="B4" value="861"/>
            <count group_id="B5" value="861"/>
            <count group_id="B6" value="4312"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.8" spread="11.1"/>
                    <measurement group_id="B2" value="58.8" spread="10.8"/>
                    <measurement group_id="B3" value="59.0" spread="11.1"/>
                    <measurement group_id="B4" value="58.2" spread="11.0"/>
                    <measurement group_id="B5" value="58.9" spread="10.7"/>
                    <measurement group_id="B6" value="58.6" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="864"/>
                    <measurement group_id="B2" value="864"/>
                    <measurement group_id="B3" value="862"/>
                    <measurement group_id="B4" value="861"/>
                    <measurement group_id="B5" value="861"/>
                    <measurement group_id="B6" value="4312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Federation of Gynecology and Obstetrics (FIGO) Stage</title>
          <description>FIGO Staging Classification: 1985.
Stage III: Tumor involving one or both ovaries with peritoneal implants outside the pelvis and/or positive retroperitoneal or inguinal nodes. Superficial liver metastasis equals Stage III. Tumor is limited to the true pelvis but with histologically verified malignant extensions to small bowel or omentum.
Stage IV: Growth involving one or both ovaries with distant metastasis. If pleural effusion is present there must be positive cytologic test results to allot a case to Stage IV. Parenchymal liver metastasis equals Stage IV.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage III:see description for details</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="724"/>
                    <measurement group_id="B2" value="749"/>
                    <measurement group_id="B3" value="743"/>
                    <measurement group_id="B4" value="744"/>
                    <measurement group_id="B5" value="721"/>
                    <measurement group_id="B6" value="3681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IV:see description for details</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="119"/>
                    <measurement group_id="B4" value="117"/>
                    <measurement group_id="B5" value="140"/>
                    <measurement group_id="B6" value="631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Site of Disease</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ovary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="748"/>
                    <measurement group_id="B2" value="752"/>
                    <measurement group_id="B3" value="737"/>
                    <measurement group_id="B4" value="752"/>
                    <measurement group_id="B5" value="751"/>
                    <measurement group_id="B6" value="3740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peritoneum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="125"/>
                    <measurement group_id="B4" value="109"/>
                    <measurement group_id="B5" value="110"/>
                    <measurement group_id="B6" value="572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Size of Residual Disease</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Microscopic only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="206"/>
                    <measurement group_id="B4" value="220"/>
                    <measurement group_id="B5" value="203"/>
                    <measurement group_id="B6" value="1044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¤ 1 cm gross disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="404"/>
                    <measurement group_id="B2" value="384"/>
                    <measurement group_id="B3" value="405"/>
                    <measurement group_id="B4" value="358"/>
                    <measurement group_id="B5" value="398"/>
                    <measurement group_id="B6" value="1949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 1 cm gross disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="263"/>
                    <measurement group_id="B2" value="262"/>
                    <measurement group_id="B3" value="251"/>
                    <measurement group_id="B4" value="283"/>
                    <measurement group_id="B5" value="260"/>
                    <measurement group_id="B6" value="1319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <time_frame>Up to 9 years</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <description>Hazard ratio for progression free survival. All hazard ratios are expressed relative to the reference regimen: Carbo/taxol.</description>
        <time_frame>From the date of enrollment to first progression or death or last contact, if alive and progression free.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carbo/Taxol</title>
            <description>Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles</description>
          </group>
          <group group_id="O2">
            <title>Carbo/Taxol/Gemcitabine</title>
            <description>Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Gemcitabine 800 mg/m2/dIV on days 1 and 8 x 8 cycles</description>
          </group>
          <group group_id="O3">
            <title>Carbo/Taxol/Doxil</title>
            <description>Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Doxil 30 mg/m2 IV every other cycle on day 1 x 8 cycles</description>
          </group>
          <group group_id="O4">
            <title>Carbo/Topotecan - Carbo/Taxol</title>
            <description>Topotecan 1.25 mg/m2/dIV days 1-3 plus Carboplatin AUC 5 IV on day 3 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles</description>
          </group>
          <group group_id="O5">
            <title>Carbo/Gemcitabine - Carbo/Taxol</title>
            <description>Gemcitabine 1000 mg/m2/dIV on days 1 and 8 plus Carboplatin AUC 6 IV on day 8 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Hazard ratio for progression free survival. All hazard ratios are expressed relative to the reference regimen: Carbo/taxol.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="864"/>
                <count group_id="O2" value="864"/>
                <count group_id="O3" value="862"/>
                <count group_id="O4" value="861"/>
                <count group_id="O5" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="14.9" upper_limit="17.2"/>
                    <measurement group_id="O2" value="16.3" lower_limit="15.1" upper_limit="17.7"/>
                    <measurement group_id="O3" value="16.4" lower_limit="15.3" upper_limit="17.5"/>
                    <measurement group_id="O4" value="15.4" lower_limit="14.7" upper_limit="16.3"/>
                    <measurement group_id="O5" value="15.4" lower_limit="14.6" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency and Severity of Observed Adverse Effects Assessed by Common Toxicity Criteria Version 2.0</title>
        <time_frame>Up to 9 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From date of enrollment onto the study to 30 days after last treatment cycle or any Adverse Event (AE) considered to be due to study treatment regardless of when it occurred.</time_frame>
      <desc>Only Serious Adverse Events(SAE) for the US-enrolled participants is able to be reported. Due to the methods in which AEs were collected &amp;/or stored, it is not possible to report only the Other(not including Serious) AEs in the appropriate table. Therefore that table is a combined set of SAEs &amp; non-serious AEs. Other AEs are Grade 2 or worse.</desc>
      <group_list>
        <group group_id="E1">
          <title>Carbo/Taxol</title>
          <description>Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles</description>
        </group>
        <group group_id="E2">
          <title>Carbo/Taxol/Gemcitabine</title>
          <description>Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Gemcitabine 800 mg/m2/dIV on days 1 and 8 x 8 cycles</description>
        </group>
        <group group_id="E3">
          <title>Carbo/Taxol/Doxil</title>
          <description>Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Doxil 30 mg/m2 IV every other cycle on day 1 x 8 cycles</description>
        </group>
        <group group_id="E4">
          <title>Carbo/Topotecan - Carbo/Taxol</title>
          <description>Topotecan 1.25 mg/m2/dIV days 1-3 plus Carboplatin AUC 5 IV on day 3 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles</description>
        </group>
        <group group_id="E5">
          <title>Carbo/Gemcitabine - Carbo/Taxol</title>
          <description>Gemcitabine 1000 mg/m2/dIV on days 1 and 8 plus Carboplatin AUC 6 IV on day 8 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="115" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="77" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="100" subjects_at_risk="767"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Neutrophils/Granulocytes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Circulatory Or Cardiac-Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Cardiac Left Ventricular Function</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Cardiac Troponin I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Vasovagal Episode</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Supraventricular Arrhythmias</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Thrombosis/Embolism</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Nodal/Junctional Arrhythmia/Dysrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Arrhythmia- Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Cardiac-Ischemia/Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Inner Ear/Hearing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Hearing-Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomatitis/Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Gi-Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Dyspepsia/Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Ascites (Non-Malignant)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Fistula-Rectal/Anal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Diarrhea (Without Colostomy)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms-Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Fever In The Absence Of Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Chest Pain Non-Cardiac Or Non-Pleuritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Or Cramping</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Pain-Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic-Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Sgpt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Sgot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy-Other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Allergic Reaction/Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="767"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Catheter-Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Infection With Unknown Anc</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Infection Documented W Grd 3/4 Neutropn.</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Infection Without Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia-Fuo Infect Not Docum</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="767"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic-Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Hypomagnesmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint, Muscle, Or Bone-Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Speech Impairment- Dysphasia/Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Seizure(S)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Cns Cerebrovascular Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Mood Alteration-Anxiety Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Dizziness/Lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Neuropathy-Sensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Neuropathy Motor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Operative Injury To Bladder/Ureter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Fistula Or Gu Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Renal/Gu-Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion (Non-Malignant)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Adult Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Wound-Infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Rash/Desquamation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Skin-Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Wound-Non-Infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Erythema Multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage-Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Rectal Bleeding/Hematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding Associated With Surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding With Grade 3 Or 4 Th</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
              <event>
                <sub_title>Hematuria (In The Absence Of Vaginal Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="774"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="767"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="767"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="857" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="856" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="852" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="843" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="849" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="746" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="826" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="806" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="782" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="800" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="821" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="838" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="818" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="830" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="825" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="319" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="675" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="438" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="460" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="645" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="508" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="700" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="603" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="647" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="685" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Other Hemotologic</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="351" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="261" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="260" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="327" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="61" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="421" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="469" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="496" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="403" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="399" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional</sub_title>
                <counts group_id="E1" subjects_affected="365" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="434" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="403" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="367" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="363" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="317" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="301" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="294" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="295" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="289" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="79" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection/Fever</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="196" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="199" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="143" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="147" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="107" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="79" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="97" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="45" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>2nd Primary</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="74" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="85" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="110" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="90" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="119" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Peripheral neurologic</sub_title>
                <counts group_id="E1" subjects_affected="207" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="232" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="207" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="134" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="144" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary/Renal</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="861"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="118" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="106" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="145" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatologic</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="64" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="862"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="860"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="846"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Linda Gedeon, BS, CCRP</name_or_title>
      <organization>Gynecologic Oncology Group Statistical and Data Center</organization>
      <phone>716-845-1169</phone>
      <email>lgedeon@gogstats.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

